ASP2905

B+

Pharmacology

ASP2905 is a KCHN3 inhibitor, which is concentrated in the frontal lobe. This potentiates the recurrent excitation of delay neurons via preventing K+ efflux out of the dendritic spine in the PFC, a central component of working memory (cf. Amy Arnsten’s research on the dlPFC, guanfacine, etc.):

ASP2905 in one study was found to be psychoactive in mice [1]

In studies ASP2905:

• Has inhibited meth-induced hyperlocomotion, but did not affect spontaneous locomotion.
• Treated certain symptoms of Schizophrenia
• Shows potential in treating ADHD [2]

KCNH3 overexpression in mice is associated with cognitive deficits, and knockout mice exhibit enhanced performance in attention.

KCNH3 knockout leads to an increased efflux of Dopamine and Acetylcholine (more significantly than dopamine) in the Medial Prefrontal Cortex.

ASP2905 does not contain many anecdotal reports.

It also seems like the only currently known KCNH3 modulator.